Home >> Allergy/Immunology >> Allergy/Immunology >> Baby Food >> Technology & Media >>

Moderate Psoriasis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 137 | Code: MRS - 18264

Moderate Psoriasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Moderate Psoriasis - Pipeline Review, H1 2015’, provides an overview of the Moderate Psoriasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Moderate Psoriasis Overview 9
Therapeutics Development 10
Pipeline Products for Moderate Psoriasis - Overview 10
Pipeline Products for Moderate Psoriasis - Comparative Analysis 11
Moderate Psoriasis - Therapeutics under Development by Companies 12
Moderate Psoriasis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Moderate Psoriasis - Products under Development by Companies 17
Moderate Psoriasis - Companies Involved in Therapeutics Development 20
AbGenomics International, Inc. 20
Almirall, S.A. 21
Amgen Inc. 22
ApoPharma Inc. 23
Avexxin AS 24
Boehringer Ingelheim GmbH 25
Convoy Therapeutics, Inc. 26
Covagen AG 27
Delenex Therapeutics AG 28
Eli Lilly and Company 29
GlycoMar Limited 30
Idera Pharmaceuticals, Inc. 31
Johnson & Johnson 32
Merck KGaA 33
OPKO Health, Inc. 34
Pfizer Inc. 35
Sandoz International GmbH 36
Soligenix, Inc. 37
Sun Pharmaceutical Industries Inc. 38
Syntrix Biosystems, Inc. 39
UCB S.A. 40
Valeant Pharmaceuticals International, Inc. 41
XenoPort, Inc. 42
Moderate Psoriasis - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
AbGn-168H - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
adalimumab biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
adalimumab biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AKP-11 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
aminopterin sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AVX-001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
baricitinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BI-655066 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
brodalumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
certolizumab pegol - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
COVA-322 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
cyclosporine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
dimethyl fumarate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
DLX-105 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
DLX-3003 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
etanercept biosimilar - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
GLY-2028 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
guselkumab - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
IDP-118 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IMO-8400 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ixekizumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
lunacalcipol - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
MSB-0010841 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
orilotimod potassium - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
PF-04965842 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SGX-301 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
tazarotene - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
tildrakizumab - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
UCB-5857 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ustekinumab - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
XP-23829 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Moderate Psoriasis - Recent Pipeline Updates 101
Moderate Psoriasis - Dormant Projects 131
Moderate Psoriasis - Discontinued Products 133
Moderate Psoriasis - Product Development Milestones 134
Featured News & Press Releases 134
Sep 11, 2014: Delenex Announces New Clinical Data 134
Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 134
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 136
Disclaimer 137

List of Tables
Number of Products under Development for Moderate Psoriasis, H1 2015 10
Number of Products under Development for Moderate Psoriasis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Products under Development by Companies, H1 2015 (Contd..2) 19
Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H1 2015 20
Moderate Psoriasis - Pipeline by Almirall, S.A., H1 2015 21
Moderate Psoriasis - Pipeline by Amgen Inc., H1 2015 22
Moderate Psoriasis - Pipeline by ApoPharma Inc., H1 2015 23
Moderate Psoriasis - Pipeline by Avexxin AS, H1 2015 24
Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 25
Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H1 2015 26
Moderate Psoriasis - Pipeline by Covagen AG, H1 2015 27
Moderate Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2015 28
Moderate Psoriasis - Pipeline by Eli Lilly and Company, H1 2015 29
Moderate Psoriasis - Pipeline by GlycoMar Limited, H1 2015 30
Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 31
Moderate Psoriasis - Pipeline by Johnson & Johnson, H1 2015 32
Moderate Psoriasis - Pipeline by Merck KGaA, H1 2015 33
Moderate Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 34
Moderate Psoriasis - Pipeline by Pfizer Inc., H1 2015 35
Moderate Psoriasis - Pipeline by Sandoz International GmbH, H1 2015 36
Moderate Psoriasis - Pipeline by Soligenix, Inc., H1 2015 37
Moderate Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 38
Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H1 2015 39
Moderate Psoriasis - Pipeline by UCB S.A., H1 2015 40
Moderate Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 41
Moderate Psoriasis - Pipeline by XenoPort, Inc., H1 2015 42
Assessment by Monotherapy Products, H1 2015 43
Number of Products by Stage and Target, H1 2015 45
Number of Products by Stage and Mechanism of Action, H1 2015 47
Number of Products by Stage and Route of Administration, H1 2015 49
Number of Products by Stage and Molecule Type, H1 2015 51
Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 101
Moderate Psoriasis - Dormant Projects, H1 2015 131
Moderate Psoriasis - Dormant Projects (Contd..1), H1 2015 132
Moderate Psoriasis - Discontinued Products, H1 2015 133

List of Figures
Number of Products under Development for Moderate Psoriasis, H1 2015 10
Number of Products under Development for Moderate Psoriasis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Products, H1 2015 16
Assessment by Monotherapy Products, H1 2015 43
Number of Products by Top 10 Targets, H1 2015 44
Number of Products by Stage and Top 10 Targets, H1 2015 44
Number of Products by Top 10 Mechanism of Actions, H1 2015 46
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46
Number of Products by Top 10 Routes of Administration, H1 2015 48
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 49
Number of Products by Top 10 Molecule Types, H1 2015 50
Number of Products by Stage and Top 10 Molecule Types, H1 2015 51

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing